Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study
Authors' conclusion
The MenACWY conjugate vaccine was less immunogenic in adolescent patients with primary or secondary immunodeficiency compared to healthy controls
Study context
- Population
- Adolescents aged 14–18 years with primary or secondary immune deficiency (incl. SLE, MCTD, vasculitis, uveitis, 22Q11 syndrome, sickle cell disease, stem cell transplantation for bone marrow failure), vaccinated in the 2018–19 catch-up campaign during the IMD-W outbreak in the Netherlands
- Participants
- 69 vs 75
- Exposure
- Adolescents with primary or secondary immune deficiency vs healthy, age-matched controls after a single dose of MenACWY-TT vaccine
- Patientsn = 69
- Healthy controlsn = 75reference
- Outcome
- MenACWY-PS-specific IgG GMCs
- Follow-up
- Before and 3-6, 12, and 24 months after vaccination
Methodological detailsaged-matched healthy controls
- Aged-matched healthy controls
Main finding
As reported in the abstract
12 months postvaccination
Adjusted GMC ratio (serogroup A)
0.26
95% CI 0.15–0.47
Patients
Adjusted GMC ratio (serogroup W)
0.22
95% CI 0.10–0.49
Patients
Observational data: associations, not effects.
Safety
- No serious adverse events reported by study participants
Original publication
Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study. Pediatr Rheumatol Online J. Published 20 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →